To overcome many of the limitations of delivering drugs to the ear, we have developed a proprietary technology that is designed to deliver drug that is retained in the ear for an extended period of time following a single local administration, which we refer to as “sustained-exposure.” Our technology utilizes a thermosensitive polymer, which transitions from a liquid to a gel at body temperature. The polymer is combined with drug microparticles to create a suspension that is retained in the ear for an extended period of time. This prolonged residence time provides high and sustained drug exposure.
Potential benefits for our product candidates include:
- Single local administration.
- High drug levels in the target location and minimal systemic exposure.
- No need for the patient to remain in a prone position for an extended period of time.
- Simple office-based administration by the ENT.
- No patient compliance concerns.
Utilizing this technology, we have advanced multiple product candidates into development, and launched our first product, OTIPRIO (ciprofloxacin otic suspension). OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement. We have a broad patent portfolio of approximately 75 issued patents and allowed patent applications and at least 100 pending patent applications covering our product candidates and indications as well as other potential applications of our technology in major markets around the world.